Dechra Veterinary Products has announced a change to the Summary of Product Characteristics (SPCs) for its Vetoryl (trilostane) Hard Capsules for Dogs.
The new lower recommended starting dose for Vetoryl – a treatment for dogs with Cushing’s syndrome – follows the publication of research and studies into the effects of reducing the initial dose rate.
Brand manager Craig Sankey explained: “Since Vetoryl capsules were first launched more than ten years ago, vets have accumulated a considerable amount of practical experience in using the product to transform the lives of dogs with Cushing’s syndrome.
“Several leading veterinary teaching establishments have carried out studies investigating the effects of reducing the initial dose rate and the published literature indicates that lower starting doses are efficacious and may reduce the risk of side effects.
The new, lower recommended starting dose is 2 mg/kg once daily, and the 10 mg capsules can now be used as a starting dose. Further guidance is also given for switching to twice daily dosing.
“Our new dosing recommendations are in line with current thinking from veterinary specialists in endocrinology and internal medicine, ensuring that Vetoryl evolves with the times and continues to restore vitality to Cushingoid dogs.”
- For further information contact the Dechra Veterinary Technical Services Team on 01939 211200, email email@example.com, or speak to your local Dechra territory sales manager.